Clinical Controversies in HIV
Rajesh T. Gandhi, MD
Professor of Medicine, Harvard Medical School
Massachusetts General Hospital, Boston, MA
Videos of live meetings of PRN in NYC are owned and published by Physicians’ Research Network, Inc.
Copyright © 2019. All rights reserved.
Rajesh T. Gandhi, M.D. is a Professor of Medicine at Harvard Medical School, and the Director of HIV Clinical Services and Education at Massachusetts General Hospital (MGH). Dr. Gandhi is the site leader of the MGH AIDS Clinical Research Site in the Harvard/Miriam AIDS Clinical Trials Unit and chair of the AIDS Clinical Trials Group (ACTG) HIV Reservoirs and Eradication Transformative Science Group. He is also the Director of the Harvard University Center for AIDS Research Clinical Core (CFAR). Dr. Gandhi is the editor of Partners ID Images, an educational infectious diseases website, and organizer of the HIV Online Provider Education (HOPE) program, an internet-based educational conference series for physicians and nurses caring for HIV-infected patients in resource-limited settings. He is also a Deputy Editor of NEJM Journal Watch Infectious Diseases and NEJM Journal Watch HIV/AIDS. Dr. Gandhi is a scientific member of the Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents, and the International Antiviral Society-USA Panel on Antiretroviral Drugs for Treatment and Prevention of HIV in Adults. Dr. Gandhi graduated from Harvard Medical School, completed his medical residency and chief residency at Brigham and Women’s Hospital, and his infectious diseases fellowship training at Johns Hopkins Hospital.
At the completion of this educational session, learners will:
- Describe options for prevention and treatment of HIV infection.
- Summarize recent insights into complications of antiretroviral therapy.
- Discuss emerging efforts to cure HIV infection.
This PRN CME activity is funded in part by unrestricted educational grants from:
Gilead Sciences; Janssen Therapeutics, a division of Janssen Products, LP; and Merck & Co.
